831 related articles for article (PubMed ID: 34135898)
21. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
Front Immunol; 2018; 9():2740. PubMed ID: 30559740
[TBL] [Abstract][Full Text] [Related]
22. Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure.
Uribe-Herranz M; Klein-González N; Rodríguez-Lobato LG; Juan M; de Larrea CF
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498529
[TBL] [Abstract][Full Text] [Related]
23. Clinical effects and applications of the gut microbiome in hematologic malignancies.
D'Angelo CR; Sudakaran S; Callander NS
Cancer; 2021 Mar; 127(5):679-687. PubMed ID: 33369893
[TBL] [Abstract][Full Text] [Related]
24. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
[TBL] [Abstract][Full Text] [Related]
25. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.
Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B
Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980
[TBL] [Abstract][Full Text] [Related]
27. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.
Feins S; Kong W; Williams EF; Milone MC; Fraietta JA
Am J Hematol; 2019 May; 94(S1):S3-S9. PubMed ID: 30680780
[TBL] [Abstract][Full Text] [Related]
28. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C
Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013
[TBL] [Abstract][Full Text] [Related]
29. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.
Kenderian SS; Porter DL; Gill S
Biol Blood Marrow Transplant; 2017 Feb; 23(2):235-246. PubMed ID: 27638367
[TBL] [Abstract][Full Text] [Related]
30. CAR T Cell Therapy for Hematological Malignancies.
Yang X; Wang GX; Zhou JF
Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
[TBL] [Abstract][Full Text] [Related]
31. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
32. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
Perez A; Al Sagheer T; Nahas GR; Linhares YPL
Front Immunol; 2024; 15():1412002. PubMed ID: 38779668
[TBL] [Abstract][Full Text] [Related]
33. The Application of CAR-T Cells in Haematological Malignancies.
Skorka K; Ostapinska K; Malesa A; Giannopoulos K
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):34. PubMed ID: 33156409
[TBL] [Abstract][Full Text] [Related]
34. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
36. Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety.
Halim L; Ajina A; Maher J
Best Pract Res Clin Haematol; 2018 Jun; 31(2):117-125. PubMed ID: 29909912
[TBL] [Abstract][Full Text] [Related]
37. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties.
Haidar G; Garner W; Hill JA
Curr Opin Infect Dis; 2020 Dec; 33(6):449-457. PubMed ID: 33009139
[TBL] [Abstract][Full Text] [Related]
38. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
39. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
40. Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice.
Wudhikarn K; Park JH
Leuk Lymphoma; 2020 Oct; 61(10):2324-2334. PubMed ID: 32522059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
